(12) PATENT APPLICATION PUBLICATION (21) Application No. : 567/MUMNP/2006 (19) INDIA (22) Date of filing of Application :15/05/2006 (43) Publication Date : 18/05/2007        Journal No. - 20/2007   (54) Title of the invention : PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS   (51) International classification :C07C213/00 (31) Priority Document No :1356/MUM/2004 (32) Priority Date :17/12/2004 (33) Name of priority country :India (86) International Application No         Filing Date :PCT/GB2005/004935 :19/12/2005 (87) International Publication No :WO2006/064283 (61) Patent of Addition to Application Number         Filing Date :NA :NA (62) Divisional to Application Number         Filing Date :NA :NA   (71)Name of Applicant :    1)CIPLA LIMITED       Address of Applicant :289 Bellasis Road, Mumbai Central, Mumbai - 400 008, Maharashtra India (72)Name of Inventor :    1)LULLA, Amar (India)    2)MALHOTRA, Geena (India)    3)RAo, Dharmaraj Ramchandra (India)    4)KANKAN, Rajendra, Narayanrao (India)    5)CHAUDHARY, Alka (India) (57) Abstract : The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8,11.9, 13.0, 18.3,28.5 ± 0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6,15.2, 15.7, 19.1, 27.2, 30.7 ± 0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7 ± 0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and optionally one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used.   Number of Pages = 59